NasdaqGS:KMDA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications.


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Kamada's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KMDA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-10.0%

KMDA

-1.2%

US Biotechs

0.7%

US Market


1 Year Return

52.9%

KMDA

34.0%

US Biotechs

20.1%

US Market

Return vs Industry: KMDA exceeded the US Biotechs industry which returned 30.6% over the past year.

Return vs Market: KMDA exceeded the US Market which returned 17.1% over the past year.


Shareholder returns

KMDAIndustryMarket
7 Day-10.0%-1.2%0.7%
30 Day-5.3%-4.4%6.4%
90 Day8.9%4.5%20.1%
1 Year52.9%52.9%36.1%34.0%22.6%20.1%
3 Year89.4%89.4%33.4%27.1%45.1%35.7%
5 Year110.7%110.7%8.5%0.8%79.7%60.3%

Price Volatility Vs. Market

How volatile is Kamada's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kamada undervalued compared to its fair value and its price relative to the market?

14.9x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KMDA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KMDA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KMDA is good value based on its PE Ratio (14.9x) compared to the US Biotechs industry average (24x).

PE vs Market: KMDA is good value based on its PE Ratio (14.9x) compared to the US market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: KMDA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: KMDA is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Kamada forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-54.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KMDA's earnings are forecast to decline over the next 3 years (-54.2% per year).

Earnings vs Market: KMDA's earnings are forecast to decline over the next 3 years (-54.2% per year).

High Growth Earnings: KMDA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: KMDA's revenue is expected to decline over the next 3 years (-13.8% per year).

High Growth Revenue: KMDA's revenue is forecast to decline over the next 3 years (-13.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KMDA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Kamada performed over the past 5 years?

72.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KMDA has high quality earnings.

Growing Profit Margin: KMDA's current net profit margins (16.9%) are lower than last year (21%).


Past Earnings Growth Analysis

Earnings Trend: KMDA has become profitable over the past 5 years, growing earnings by 72.1% per year.

Accelerating Growth: KMDA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: KMDA had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Biotechs industry average (1.8%).


Return on Equity

High ROE: KMDA's Return on Equity (13.6%) is considered low.


Next Steps

Financial Health

How is Kamada's financial position?


Financial Position Analysis

Short Term Liabilities: KMDA's short term assets ($166.2M) exceed its short term liabilities ($25.4M).

Long Term Liabilities: KMDA's short term assets ($166.2M) exceed its long term liabilities ($5.6M).


Debt to Equity History and Analysis

Debt Level: KMDA's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: KMDA's debt to equity ratio has reduced from 9.8% to 0.4% over the past 5 years.

Debt Coverage: KMDA's debt is well covered by operating cash flow (3248.8%).

Interest Coverage: KMDA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Kamada current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KMDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KMDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KMDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KMDA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KMDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Amir London (51 yo)

5.08yrs

Tenure

US$737,932

Compensation

Mr. Amir London has been the Chief Executive Officer at Kamada Ltd. since July 1, 2015. Mr. London served as an Senior Vice President of Business Development at Kamada Ltd. from December 9, 2013 to July 1, ...


CEO Compensation Analysis

Compensation vs Market: Amir's total compensation ($USD737.93K) is below average for companies of similar size in the US market ($USD2.03M).

Compensation vs Earnings: Amir's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Amir London
Chief Executive Officer5.08yrsUS$737.93k0.094%
$ 344.8k
Chaime Orlev
Chief Financial Officer2.67yrsUS$322.64k0.026%
$ 95.5k
Eran Nir
Vice President of Operations3.75yrsUS$306.45k0.032%
$ 117.4k
Orna Naveh
General Counsel & Corporate Secretaryno datano datano data
Hanni Neheman
Vice President of Marketing & Sales0.58yrno data0.0077%
$ 28.0k
Ariella Raban
Vice President of Human Resources2.25yrsno data0.022%
$ 79.9k

2.7yrs

Average Tenure

50yo

Average Age

Experienced Management: KMDA's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Leon Recanati
Independent Chairman7.42yrsno data8.03%
$ 29.3m
Ishay Davidi
Independent Director0.67yrno datano data
Amiram Boehm
Independent Director0.67yrno datano data
David Tsur
Director30.58yrsUS$300.00k1.73%
$ 6.3m
Lilach Asher-Topilsky
Independent Director0.67yrno datano data
Jonathan Hahn
Director10.42yrsno data0.27%
$ 981.5k
Avraham Berger
Independent Director4yrsno datano data
Karnit Goldwasser
Independent Director0.67yrno datano data

2.3yrs

Average Tenure

58yo

Average Age

Experienced Board: KMDA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.


Top Shareholders

Company Information

Kamada Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kamada Ltd.
  • Ticker: KMDA
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₪1.246b
  • Listing Market Cap: ₪365.494m
  • Shares outstanding: 44.52m
  • Website: https://www.kamada.com

Number of Employees


Location

  • Kamada Ltd.
  • 2 Holzman Street
  • Science Park
  • Rehovot
  • 7670402
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KMDATASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2005
KMDANasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDSep 2005
K3MBST (Boerse-Stuttgart)YesOrdinary SharesDEEURSep 2005

Biography

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory pr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/12 23:48
End of Day Share Price2020/08/12 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.